EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will ...

EMERYVILLE, Calif., June 03, 2025--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO), today announced the NMU-Symphony™ system, ...

Peters will oversee employee engagement, retention and acquisition as Nutcracker continues to grow EMERYVILLE, Calif., March 07, 2023--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology ...

Financing round led by returning investor ARCH Venture Partners Enables accelerated development of therapeutic pipeline built upon its proprietary RNA technology platform Industry veteran Michael F.

NTX-471 had similar activity to conjugates of existing anti-CD47 therapeutics, without anemic side effects Mice treated with mNTX-250 for HPV-16-transformed tumors became tumor-free and remained so ...